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A B S T R A C T
Despite the impact of the human microbiome on health, an appreciation of microbial ecology is yet to
be translated into mainstream medical training and practice. The human microbiota plays a role in the
development of the immune system, in the development and function of the brain, in digestion, and in
host defense, and we anticipate that many more functions are yet to be discovered. We argue here that
without formal exposure to microbiology and ecology—fields that explore the networks, interactions and
dynamics between members of populations of microbes—vitally important links between the human
microbiome and health will be overlooked. This educational shortfall has significant downstream effects
on patient care and biomedical research, and we provide examples from current research highlighting
the influence of the microbiome on human health. We conclude that formally incorporating microbiol-
ogy and ecology into the premedical curricula is invaluable to the training of future health professionals
and critical to the development of novel therapeutics and treatment practices.
K E Y W O R D S : premedical curricula; microbiology; human microbiome; ecology
INTRODUCTION
The influential American microbiologist D. H.
Bergey was an advocate for adding bacteriology as
an essential component of the general training of
biology students and those seeking to obtain med-
ical training as early as 1915 [1]. One hundred years
later, in 2015, it is clear that many organ systems and
physiological functions in the human body are
modulated by small molecules derived from the
microbiota and that the microbiome is a key deter-
minant of human health (Table 1). Moreover, the
human body can be viewed as a complex and
multifaceted ecosystem, and human health can be
interpreted in part as a product of the ecosystem
services that are delivered by its resident microbiota
[2]. As stressed by Zhou et al. [3], each of us is
composed of diverse habitats that are exposed to
review
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Table 1. Examples of medical specialties and organ systems where the microbiome has been suggested
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and subsequently can respond to variations in our
external environment. In addition, the dynamics of
microbial communities associated with these habi-
tats can be strongly modulated by local interactions
with our immune, endocrine and nervous systems
[3]. Each habitat provides a unique niche space for
the growth and survival of indigenous and invading
microbes [3], and shifts of the human body from a
‘healthy’ non-diseased state to a diseased condition
are often accompanied by major alterations in
microbial growth and community composition
(Table 1). We thus argue here that formal inclusion
of microbiology and ecology is essential in the pre-
medical biology curriculum because of the intricate
and interwoven relationships that we share with our
microbial partners: archaea, bacteria, viruses and
microeukaryotes such as fungi.
In this review, we highlight the role of ecological
and microbe–host interactions in human health, and
we outline how exposure to microbial ecology in pre-
medical curricula can affect clinical practice. The
broader topic of how the human ecosystem interacts
with environmental ecosystems, although equally
important, is not covered in this review as it has been
discussed elsewhere [39–41]. We also provide brief
examples that demonstrate the important potential
role of the human gut microbiome under four differ-
ent patient settings: (i) the administration of antibi-
otics, (ii) the presence of metabolic disorders, (iii)
the development of cancer and (iv) the pharmaco-
kinetics of drugs within the patient. For each of these
four examples, we highlight the potential integration
of practices in the clinic with discoveries in basic
microbiome research and ecology.
WHY INTEGRATE MICROBIOLOGY AND
ECOLOGY INTO THE PREMEDICAL
CURRICULA?
Efforts to characterize microbial communities
residing within the human body during the last dec-
ade have greatly increased our understanding of mi-
crobial community composition and diversity in
health and disease. However, despite characterized
connections between the human microbiota and
health, a profound disconnect currently exists be-
tween research on the human microbiome and the
applied health fields. This disconnect is reflected in
the limited exposure to the principles of microbiol-
ogy and ecology that medical professionals receive
during their premedical and medical education and
training. Here, when we refer to premedical training,
we are referring to undergraduate education.
Admission requirements to medical schools do
not include microbiology and ecology, and the
required biology coursework is mostly centered
around genetics and cell biology with an emphasis
on human biology. In medical school, microbiology
is often taught in the context of pathogenesis.
Moreover, the principles of ecology, which broadly
apply to the human microbiome [2], are not yet well
integrated into standard premedical courses.
Perhaps because formal classroom exposure to
the principles of microbiology and ecology is often
absent from premedical curricula (Table 2), many
human health professionals approach disease pri-
marily through the lens of mammalian anatomy
and physiology. This educational framework leads
to a lack of integration of clinical practices with basic
microbiological and ecological research.
Several examples of the diverse ecological prin-
ciples that apply to the human host and its
associated microbiome are outlined in Box 1, and
examples of the kinds of microbe–microbe and mi-
crobe–host interactions that can occur within the
human body are shown in Fig. 1. The integration of
ecology with (i) the biochemistry of microbial meta-
bolic processes and (ii) the interactions of the
microbiome with human physiology, e.g. immune
responses, is lacking in the more topic-segregated
courses taught currently. Teaching these concepts
concurrently will provide a common language to en-
courage communication and the exchange of ideas
among medical students, clinicians and basic re-
searchers. We also believe that there is great value
in combining reductionist approaches (e.g. a focus
on the molecular biology and biochemistry of the
Table 2. Current minimum
background needed for MCAT 2015
and acceptance to Medical School
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box 1 . key ecological topics and principles that apply to the
human host and its associated microbiome
Population Ecology. A population is a group of individuals of the same organism or cell type that co-occur in the same
location and time. For example, Costerton et al. [43] stress that most microbial pathogens must persist and multiply in
their infected system in order to cause deleterious effects. Thus, whether the initial infection event involves a single
virion, fungal propagule or bacterial cell, the invader typically must replicate to large population densities before its
presence significantly influences the health of its human host. Similarly, the replication and growth of immune cells (e.g.
protective B and T lymphocytes), as well as potential pathogen targets (e.g. uninfected red blood cells within the
bloodstream that can be targeted by the Plasmodium malaria parasite), are cellular populations [44]. Moreover, Smith
[45] discusses relationships for resource-limited growth of populations of a hypothetical pathogen (P) and of hypothetical
host cells (H), and Smith et al. [46] have recently demonstrated extremely strong effects of pre-infection T cell population
growth rate on virus replication following experimental infection with a hybrid HIV-SHIV retrovirus.
Metapopulation Ecology. Populations must also be considered in a spatial context. Multiple populations of the same
organism or cell type can co-occur in the same time, but at different locations: thus, a metapopulation is a ‘population of
populations’ [47]. These spatially dispersed subpopulations occur in patches of suitable habitat surrounded by areas of
unsuitable or as-yet uninvaded habitat. Individual subpopulations are connected by the spatial movements of migrating
individuals, and thus any given subpopulation within the entire metapopulation can be reestablished and rescued from
extinction by colonization events from distant subpopulations [47]. Mittelbach [47] provides important examples of
metapopulation dynamics such as source–sink interactions that we consider to be potentially relevant to human host–
human microbiome interactions.
Community Ecology. A community is defined as a group of different organisms, species, or cell types that co-occur in the
same location and time. Community ecologists thus grapple with and attempt to predict the structure and dynamics of
multispecies ensembles that live within the same habitat, landscape or region [48]. For example, the human circulatory
system contains a complex community of differentiated blood cell types that have different cell architectures and func-
tions. Similarly, the human gut contains trillions of coexisting and often closely interacting microbes of different phylo-
genetic origins. Every human can be viewed as a unique set of microbial assemblages occupying different habitats across
the human body governed by the fundamental processes of community ecology [2]. We know relatively little about how
within-host microbial communities respond to local and regional factors that affect key processes such as host repro-
duction, resistance to novel microbes or microbial transmission rates [49]. However, among the multiple community
modules outlined by Holt and Dobson 48], we suggest that at least six kinds of interactions potentially may apply to
humans and their microbiome: food chain (a linearly arrayed, hierarchical network of consumers and their resources);
exploitative competition, also known as resource competition (in which two or more species compete directly for a growth-
limiting nutrients); interference competition, also known as contest competition (in which individuals interfere with the
resource acquisition and survival of other individuals, e.g. via the production of toxins); niche partitioning (in which two or
more species reduce the magnitude of their interspecific competition by specializing upon different resources); predation
on competing prey (in which the outcome of resource competition between two prey species is influenced by the presence
of a shared predator); apparent competition (the appearance of resource competition between two non-interacting prey
species that are differentially consumed by a shared predator); and keystone predation (in which a shared predator
facilitates the coexistence of prey species). Robinson et al. [50] have recently reviewed the ecology of host-associated
microbial communities, and Fierer et al. [51] have applied concepts developed by plant and animal ecologists to better
understand and predict the spatial and temporal patterns of human microbial communities. Explicit theoretical and
empirical tests of the hypothesis that principles of community ecology directly apply to human biomedicine also can be
found in [44, 52, 53].
Metacommunity Ecology. Just as the dispersal of individuals may link the dynamics of subpopulations that are separated
in space, dispersal across communities can link local communities into a larger metacommunity. Mittelbach [47] has
provided important examples of metacommunity dynamics such as competition-coexistence tradeoffs in patchy environ-
ments that we consider to be potentially relevant to human host–human microbiome interactions, and Holt [54] has
explored the dynamics of human pathogens in a biogeographical and landscape context.
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box 1 . continued
Ecosystem Ecology. The human host can be viewed as an ecosystem composed of interacting populations and
communities [3]. Similar to other kinds of ecosystems, the human body exhibits strong and predictable flows of energy
and resources, in this case, the inputs and outputs of energy and nutrients that are derived from ingested food and water.
Analogous to the differences that exist between pre- and postinvasion nutrient and energy dynamics in pathogen-invaded
terrestrial ecosystems [55, 56], pathogen-invaded human bodies can be expected to exhibit changes in nutrient and energy
dynamics that vary strongly with the intensity and outcome of infectious disease. Moreover, we suggest that the prin-
ciples of resource-ratio theory and ecological stoichiometry, which considers how the balance of energy and chemical
elements is influenced by organisms and their metabolic activities [57], will apply to the human host and its microbiome.
For example, the guts of infants fed breast milk without supplemental iron have been found to develop a microbial
community composed primarily of non-toxigenic Lactobacillus species; in contrast, infants fed iron-supplemented formula
developed a different intestinal community that included potentially toxigenic bacteria such as those belonging to the
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Figure 1. Examples of internal and external factors that can lead to conditions associated with altered microbial communities (modified from Fig. 4 in [58]). A. Key
microbe–microbe interactions. Four important kinds of ecological interactions can strongly regulate the growth and population dynamics of a microbial community
residing in or upon a human host. (i) Resource competition. The ability of multiple microbial species to compete for growth-limiting resources such as the essential
nutrient glucose (red circles) may in part determine their local survival and population dynamics. Note that microbes can also compete for space and for docking
sites. (ii) Nutrient cross-feeding. Microbial species 1 produces an essential nutrient such as folate (orange circles) that is in turn consumed by and enables the
persistence of a co-resident auxotrophic species (Microbe 2) that requires this resource for growth. (iii) Antibiosis. One microbial species or strain (Microbe 1) may
produce an antibiotic (yellow triangles) that is excreted and inhibits or kills another susceptible microorganism (Microbe 2). (iv) Predation. Attacks by a predator (in
this example, a bacteriophage virus) results in the infection and death of susceptible prey (in this case, a gut bacterium). (Inspired by and greatly revised from
Figure 1 by Seth and Taga [59]). B. Key microbe–host interactions. Four important kinds of ecological interactions can strongly influence the growth and population
dynamics of interacting microbial and host cells. (i) Resource competition. Members of the host’s resident microbiome may compete with host cells for growth-
limiting resources such as the essential nutrient glucose (red circles). (ii) Metabolite production, conversion and nutrient cross-feeding. One cell type (in this case, the
host cell) may produce an essential resource (orange circles) which is then consumed and metabolized to a new metabolite by microbial cells; this microbial
metabolite (purple circles) is excreted and is subsequently consumed and used by host cells. Microorganisms can generate metabolites and bacterial compo-
nents, either of which can interact with receptors on host cells, or have other pharmacological effects on multiple host pathways. (iii) Predation. Predation of
microbial cells (black rectangle) may occur by phagocytic host cells. (iv) Physicochemical changes. Microbial cells may excrete non-nutrient metabolic products (in
this case, protons) that can alter the local environment and influence the growth and reproduction of host cells. (Inspired by and greatly revised from Figure 1 by
Seth and Taga [59]).
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toxin A and B proteins which lead to Clostridium
difficile colitis) with broader systems-based
approaches (e.g. a focus on ecological responses
of the gut microbial community during C. difficile
infection) to better understand the human
microbiome’s contributions to health and disease.
THE HUMAN MICROBIOME IN HEALTH
AND DISEASE
The human–microbe partnership has coevolved and
coadapted into a remarkably stable and diverse bio-
logical ecosystem [60, 61], in which the abundance of
resident microbial cells exceeds that of our own body
cells by approximately 3- to 10-fold [62]. These host-
associated microorganisms provide vital ecosystem
services that include food processing and digestion
[61]; production of vitamins [63]; modulation of epi-
thelial barriers [64]; immune system development
and response [65–67]; and defense against invading
microbial pathogens [68–70]. The microbiome has
been suggested to play a role in modulating behav-
ior, cognition and mood [71, 72].
The community structure and activity of microbial
assemblages can vary strongly, both across different
sites on an individual body and across different
human populations, diets and health conditions
[63, 73–77]. While it is widely accepted that infants
receive their first major inoculation of microorgan-
isms during the birth process, recent research sug-
gests that initial microbial exposure may occur prior
to birth [58, 78, 79]. Both the method of delivery and
subsequent environmental exposures (e.g. breast-
feeding, skin-to-skin contact between mother and
newborn, level of early antibiotic exposure, diseases
and childhood diet) reshape the initial microbial com-
munity structure, and over time act to establish the
microbiota that are characteristic of adults [80–86].
The human microbiome is characterized by a net-
work of microbe–microbe and microbe–host inter-
actions that is typically resistant to modest
fluctuations in diet, hormones, immune response
and invasions by pathogenic and non-pathogenic
microbes [87–89]. Nonetheless, strong perturb-
ations such as treatment with antibiotics can lead
to profound changes in microbial community struc-
ture from which the microbiome sometimes never
completely recovers and can have a substantial in-
fluence on human health [90–92]. With the exception
of C. difficile-associated colitis, the instigating fac-
tors that lead to diseases and conditions associated
with altered microbial communities are poorly
understood. Examples of potential ecological inter-
actions that can occur between the microbial com-
ponents of the human microbiome and its host are
illustrated in Fig. 1.
Culture-independent methods, which permit dir-
ect analysis of DNA from a sample rather than
cultured microorganisms, enable investigations of
many aspects of microbial communities inhabiting
the human body. The evolution of knowledge and
technology in ecology, microbiology, biochemistry,
immunology as well as other fields makes integra-
tion of these disciplines with medicine a natural next
step. In the four sections later, we have chosen to
focus more detailed discussion on the clinical rele-
vance of the gut microbiota, but similar principles
can be applied to other human body sites where mi-
crobe–microbe and microbe–host interactions can
impact health and disease. We also acknowledge
that the microbiota of the gut can potentially modu-
late mental health, immunity and many other clinic-
ally relevant issues in human medicine. However,
these additional issues are not reviewed here.
ANTIBIOTICS PERTURB THE GUT
MICROBIOME
Historically, medical microbiology has focused pri-
marily on the eradication of pathogens. Common
medical practices include the prescription of antibi-
otics to treat bacterial infections. However, extended
use of antibiotics unintentionally perturbs the com-
position of the human microbiota by killing off indi-
genous bacteria in addition to pathogens [93]. The
removal of indigenous microorganisms invariably af-
fects community composition and the provision of
beneficial ecosystem services to humans. Although
broad-spectrum antibiotics have saved countless
lives and are a necessary tool in fighting off harmful
infections, they also select for resistant bacteria [94],
increase horizontal gene transfer (which can lead to
the spread of antibiotic resistance-associated genes)
[95], and are likely to alter microbial physiology and
behavior by acting as signaling molecules [96].
During microbial succession following antibiotic
treatment, opportunistic pathogens can easily colon-
ize the human body and proliferate without facing
intense competition for resources from other mem-
bers of the local microbial community [97]. Such op-
portunists include C. difficile, which commonly
appears in secondary infections in hospital patients
previously given antibiotic treatments [98–100].
Antibiotics can significantly influence the
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composition and function of the human microbiota;
the implications of these changes and the ability of
the community to resist change or rebound (resili-
ence) are still not fully understood.
Current clinical approaches to ameliorate recur-
rent C. difficile infections include reintroducing
microorganisms from a healthy individual to the pa-
tient’s perturbed microbiome via the provision of
probiotics and/or fecal microbiota transplants that
amend a C. difficile-colonized patient’s gut with
microbiota from a non-diseased donor [100]. Both
of these therapeutic approaches involve deliberate
ecological manipulations of the gut ecosystem.
Although the use of probiotics has shown limited
success in treating C. difficile infections, particularly
in patients with recurrent disease [101], fecal micro-
biota transplants, in contrast, can result in a dra-
matic decrease in the symptoms of C. difficile in
patients with chronic recurrent disease and provide
strong empirical support for fecal microbiota trans-
plants as a novel therapy [102, 103]. Moreover, fecal
microbiota transplants are being considered for ap-
proval by the U.S. Food and Drug Administration
[102–105], a compelling reason for this ecological
approach to be introduced to nascent medical
professionals.
OBESITY, METABOLIC DISORDERS AND
INFLAMMATORY DISEASES
Obesity affects 35% of American adults and ac-
counts for 10% of annual U.S. medical expenses
[106]. While human genetics, diet and environment
all strongly influence the incidence of obesity, a dec-
ade of research suggests that the gut microbiome
may also play a prominent role [107–109]. For ex-
ample, gut microbiota transplantation trials in
humans found that obese volunteers who received
a lean donor microbiota exhibited improved insulin
sensitivity over 6-week post-transplant period [110].
In addition, increasing evidence points to the pres-
ence of the inflammation-inducing microorganisms
in obese individuals, and it has been hypothesized
that the development of obesity and metabolic dis-
orders may be linked to chronic gut inflammation
[111–113]. Chronic inflammation is at the root of
different conditions, including allergies, periodon-
titis and autoimmune disorders. Inflammation is,
therefore, a common problem in almost every
branch of medicine, and as such, it is crucial to rec-
ognize and understand the ecological processes that
can lead to altered microbial community compos-
ition and function.
Just as gut microbes have evolved in the nutri-
tional environment of the human intestine, human
evolution has been driven by the services that gut
microbes provide to health, such as immune system
regulation, metabolism and defense against patho-
gen invasion. Thus, modulations to the gut micro-
bial composition that jeopardize these services
could adversely affect human health. Because modi-
fications in diet have been shown to rapidly alter
microbial community composition [114], diet ma-
nipulation could help treat a number of different
metabolic disorders, including inflammatory bowel
diseases, obesity and kwashiorkor, a maladaptive
phenotype of malnutrition common in the develop-
ing world [115]. Standard undergraduate microbiol-
ogy courses delve into cell physiology and
metabolism of microorganisms, topics essential to
understanding how our gut microbiota functions
and responds to external outputs. Adding instruc-
tional material related to microbial community com-
position and function is an important first step
toward understanding how nutrition and supple-
ments could potentially aid in treatment of meta-
bolic disorders.
POTENTIAL ROLE OF GUT MICROBIOTA
IN CANCER DEVELOPMENT
Formal inclusion of the concepts of microbe–mi-
crobe and microbe–host interactions during the pre-
medical education, as well as microbial physiology
and metabolism, would help to encourage phys-
icians to search for effective methods to impede or
prevent microbe-associated cancers. Carcinogens
and risk factors for cancer exist within the human
microbiome, and cancers induced by microorgan-
isms account for 20% of all fatal cancers in humans
[116]. Most known microbially induced cancers are
caused by human papilloma viruses, hepatitis B and
C viruses and the bacterium Helicobacter pylori
[117–119]. Recently, Zackular et al. [120, 121] have
shown that specific microbial communities can drive
tumor formation in the colon and that these
communities can serve as early biomarkers of tumors.
Cancer is a complex, multifactorial disease and its
susceptibility is highly dependent on interactions
between human cells and their surrounding environ-
ment. Research suggests that microorganisms can
potentially modulate tumor growth via three major
processes: (i) by metabolizing dietary nutrients into
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carcinogens or tumor-suppression agents [122,
123]; (ii) by inducing or suppressing inflammation
[124–128]; and (iii) by causing DNA damage to host
cells [129]. It is worth noting that while many foods
have been associated with a heightened risk of can-
cer, it is the resident microbial community that ac-
tively converts them into compounds that can cause
DNA damage or inflammation of host tissues [130].
For example, gut microbes produce DNA-damaging
compounds via fermentation, which may provide the
link between the previously established association
of red meat consumption and cancer development
[122, 130–132]. Likewise, it has been found that com-
mensal Clostridium species which, metabolize pri-
mary bile acids into carcinogenic deoxycholic acid
(DCA), may contribute to the oncogenesis of colo-
rectal and liver cancers [123, 133]. Although antibi-
otics could theoretically eliminate clostridia that
synthesize the unfavorable DCA, tumor suppression
was also accomplished in mouse models by inhibit-
ing enzymes in the DCA metabolic pathway [123].
Inflammation triggered by microorganisms is not
only a necessary defense mechanism against patho-
gens but also causes significant damage to host cells
and DNA by releasing high amounts of inflamma-
tory signaling molecules and reactive oxygen and
nitrogen species [124, 127]. Furthermore, inflamma-
tion and cancer are complex processes under the
control of many factors, and the underlying mechan-
isms of their interplay remain obscured. The recruit-
ment of leukocytes, lymphocytes and other
inflammatory cells to the site of inflammation re-
sults in the release of growth factors and cytokines
that could contribute to the progression of tumors
by stimulating cell proliferation, differentiation and
vascularization [33, 124, 127, 134].
Formal inclusion of the concepts of microbe–mi-
crobe and microbe–host interactions, as well as mi-
crobial physiology and metabolism during the
premedical education would encourage physicians
to search for effective methods to impede microbial
carcinogen metabolism. For example, negative con-
sequences of commensal microbial metabolism
may be better mitigated by targeting specific micro-
bial enzymes and cofactors through selective inhibi-
tors in combination with cancer drugs [135]. It is
important to note, however, that the biology behind
the microbe–host interaction in the cancer develop-
ment is complex. For example, while H. pylori is a
causative agent of gastric cancer, it might have a
protective role in esophageal cancer [136, 137].
We stress that our discussion of the human
microbiome’s role in cancer has neither touched
on the role that commensal microbes play in the
metabolism of compounds that reduce the risk of
cancers nor explained how commensal microbes
might influence inflammation or modify the efficacy
of chemotherapeutic agents. However, it does serve
to help demonstrate the potential benefits of a para-
digm shift in the way premedical and medical stu-
dents are educated about human-associated
microbes and how cancer is studied and treated.
GUT MICROBIOME EFFECTS ON DRUG
PHARMACOKINETICS
The human-associated microbiota also possess di-
verse metabolic pathways that allow them to directly
or indirectly metabolize xenobiotic substrates.
Currently, gut microorganisms are known to modu-
late the metabolism of more than 40 pharmaceutical
compounds [138, 139]. For example, Clostridium
sporogenes plays an important role in reductive me-
tabolism of the anti-seizure drug zonisamide [140],
while Eggerthella lenta can convert the cardiac glyco-
side digoxin into an inactive form [138, 141, 142].
Substrate competition between somatic and micro-
bial cells in the gut can also lead to undesirable toxin
buildup. For example, anaerobic taxa present in rat
feces can convert the analgesic phenacetin into a
toxic metabolite associated with methemoglobin-
emia and nephritis [143]. Furthermore, microbial
ß-glucuronidases convert a detoxified species of
the cancer drug irinotecan back into its active form,
facilitating drug toxicity [144]. Microbial metabolites
may also serve as competitive inhibitors to human
enzymes; this is the case with the popular over-the-
counter analgesic acetaminophen. In individuals
whose gut microbiota produce high levels of p-cre-
sol, the ability to detoxify acetaminophen is reduced
[145]. The microbial metabolite p-cresol competi-
tively inhibits a human sulfotransferase, which sul-
fonates acetaminophen into a non-toxic derivative.
The microbial metabolite p-cresol may competitively
inhibit human sulfotransferases. Unsulfonated or
unglucuronidated acetaminophen can be oxidized
by the cytochrome P450 system and potentially other
oxidative enzymes into hepatotoxic metabolites as
reviewed in [146].
It is important to view humans in intimate asso-
ciation with their microbiota, as these microorgan-
isms likely hold the key that explains some of the
observed person-to-person variability in drug
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metabolism and responses. One way to prevent
drug toxicity is to screen for the key microorganisms
or microbial genes that are involved in drug metab-
olism. For example, urinalysis can detect production
of bacterial metabolites such as p-cresol, the metab-
olite implicated in acetaminophen hepatotoxicity
[145]. Community sequencing platforms would be
used to screen for the abundance of Clostridium
sporogenes and Bifidobacterium bifidum, the taxa that
primarily reduce zonisamide into its inactive form
[140]. Matrix-assisted laser desorption/ionization-
time of flight (MALDI-TOF) and liquid chromatog-
raphy/mass spectrometry could detect protein
levels of microbial ß-glucuronidases or microbial
zonisamide reductases. Another strategy to predict
microbial drug transformations would be to admin-
ister a tiny dose of the drug and then to analyse pa-
tient’s urine or stool samples for microbial
derivatives. Physicians could also consider alternate
methods of drug administration that result in min-
imal to no direct contact with the gut microbiome. In
one study, inactivated microbial byproducts of di-
goxin were less abundant in patients with intraven-
ous delivery rather than ingestion [141, 147],
perhaps because the intravenous delivery pathway
of digoxin largely bypassed the intestinal microbiota.
We suggest that a solid foundation in microbial
ecology during premedical education would encour-
age physicians to be aware of potential microbial
influences on drug metabolism and to search for
effective means to activate or de-activate microbial
metabolisms that interfere with drug effectiveness in
their patients. This valuable microbiological per-
spective on drug administration could assist in the
evaluation of drug activity and efficacy and help to
prevent or diminish undesirable drug toxicity.
CONCLUSIONS
Our resident microbiota play important roles in
homeostatic physiology and a host of chronic dis-
ease conditions. Nearly all of these interactions are
mediated through energy and metabolite exchange
between human and microbial cells, and through the
modulation of human and microbial gene expres-
sion [91]. Physicians need access to specific, quan-
titative metrics that can objectively be used to assess
their patients’ health state (e.g. urinalyses; blood cell
counts and serum chemistry; concentrations of key
enzymes and hormones in tissues and fluids).
Physicians also may strongly benefit from analysing
their patients’ microbiome for biomarkers that can
be used to identify microbe-associated health con-
ditions. For example, we anticipate that microbial
methods such as community profiling,
metagenomics, RNA sequencing, and MALDI-TOF
spectrometry almost certainly will become standard
components of diagnostic testing. These important
new tools provide doctors with profiles of human
microbiome composition and gene expression that
can, in turn, be used for disease analysis, tracking
and treatment. We strongly believe that an improved
knowledge of microbiological concepts will contrib-
ute to the improved diagnosis and treatment of
human diseases in future.
In this review, we therefore strongly advocate for
the inclusion of microbiology and ecology in pre-
medical curricula. As noted by Dienstag [148], ‘A sick
patient does not represent a biochemistry problem,
an anatomy problem, a genetics problem, or an im-
munology problem; rather, each person is the prod-
uct of myriad molecular, cellular, genetic,
environmental, and social influences that interact
in complex ways to determine health and disease’.
Premedical teaching should reflect this diversity and
should cut across multiple disciplines.
Although the influences of our microbiota on our
health are not yet fully understood, one thing is clear:
our bodies cannot be viewed independently of the
diverse and highly active microbial inhabitants that
interact with us. Because the gut microbiota has glo-
bal effects on human physiology, the relationship
between commensal microbes and the human body
is expansive. Although we currently know the most
about the gut microbiome and its effects on our
health, future studies of the microbiomes of the skin,
mouth and other body habitats are equally import-
ant. Whether they occur within the gut or elsewhere,
the ecological processes that mediate microbial spe-
cies richness or even the survival of just one micro-
bial taxon, can potentially affect human health.
Finally, we want to state that while work in the
human microbiome field is exciting and rapidly pro-
gressing, many studies are preliminary and focus on
model systems. Further work is required to demon-
strate the utility of basic microbiome research to
patient populations, another reason that clinicians
are such a critical and missing piece of the puzzle.
In our opinion, enhancing undergraduate micro-
biology and ecology coursework on premedical
tracks will provide health professionals with valuable
new insights into the human body as a partnership
with its microbial inhabitants. With these important
foundations in microbial ecology, future medical
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professionals can pursue clinical training in post-
graduate programs with perspectives that will allow
them to reassess and reevaluate traditional proto-
cols and treat their patients with foundational
microbiome research in mind. Why not start by
building a strong understanding and appreciation
of the human microbiome in the undergraduate
classroom as a standard part of the premedical
curricula?
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